Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Toxicol (Phila) ; 54(7): 597-600, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27219910

RESUMO

CONTEXT: Paralepistopsis acromelalga, formerly known as Clitocybe acromelalga, is a rare poisonous mushroom. The mycotoxins in this mushroom cause symptoms resembling those of erythromelalgia; however, its pathogenesis remains unclear. In this report, a patient who received nicotinic acid treatment for P. acromelalga poisoning and radiological evaluation for erythromelalgia has been presented. Case detail: A 59-year-old woman was hospitalized for redness, swelling, and burning pain in her extremities that rendered difficulty in walking, and a diagnosis of P. acromelalga poisoning was made by detailed interview and mushroom identification. She was treated with intravenous nicotinic acid for 17 days followed by oral nicotinic acid amide for 2 months. She exhibited rapid symptomatic improvement and walked independently after 11 days of initial treatment. Initial MRI of her feet revealed toe-dominated subcutaneous thickening. After nicotinic acid treatment, those radiological findings improved dramatically. DISCUSSION: The subcutaneous thickening evident on MRI indicated P. acromelalga poisoning-induced erythromelalgia involved subcutaneous inflammatory edema. The typical duration of edema without treatment is more than a month. The improvement on MRI after nicotinic acid treatment indicated that the adequate vasodilation induced by nicotinic acid contributed to resolution of the symptoms. Nicotinic acid was associated with the improvement of the edematous changes caused by the P. acromelalga intoxication.


Assuntos
Agaricales , Imageamento por Ressonância Magnética , Intoxicação Alimentar por Cogumelos/tratamento farmacológico , Micotoxinas/intoxicação , Niacina/uso terapêutico , Administração Intravenosa , Relação Dose-Resposta a Droga , Eritromelalgia/tratamento farmacológico , Eritromelalgia/etiologia , Feminino , Hospitalização , Humanos , Pessoa de Meia-Idade , Intoxicação Alimentar por Cogumelos/complicações , Intoxicação Alimentar por Cogumelos/diagnóstico
2.
Life Sci ; 95(1): 22-8, 2014 Jan 24.
Artigo em Inglês | MEDLINE | ID: mdl-24368140

RESUMO

AIMS: Transplantation of bone marrow mononuclear cells (BMMCs) exerts neuroprotection against cerebral ischemia. We examined the therapeutic timepoint of allogeneic BMMC transplantation in a rat model of focal cerebral ischemia, and determined the effects of repeated transplantation outside the therapeutic window. MAIN METHODS: Male Sprague-Dawley rats were subjected to 90 minute focal cerebral ischemia, followed by intravenous administration of 1 × 10(7) allogeneic BMMCs or vehicle at 0, 3 or 6 h after reperfusion or 2 × 10(7) BMMCs 6 h after reperfusion. Other rats administered 1 × 10(7) BMMCs at 6 h after reperfusion received additional BMMC transplantation or vehicle 9 h after reperfusion. Infarct volumes, neurological deficit scores and immunohistochemistry were evaluated 24 or 72 h after reperfusion. KEY FINDINGS: Infarct volumes at 24 h were significantly decreased in transplantation rats at 0 and 3 h, but not at 6 h, after reperfusion, compared to vehicle-treatment. Even high dose BMMC transplantation at 6h after reperfusion was ineffective. Repeated BMMC transplantation at 6 and 9h after reperfusion reduced infarct volumes and significantly improved neurological deficit scores at 24 and 72 h. Immunohistochemistry showed repeated BMMC transplantation reduced ionized calcium-binding adapter molecule 1, 4-hydroxy-2-nonenal and 8-hydroxydeoxyguanosine expression at 24 and 72 h after reperfusion. SIGNIFICANCE: Intravenous allogeneic BMMCs were neuroprotective following transient focal cerebral ischemia, and the therapeutic time window of BMMC transplantation was >3 h and <6 h after reperfusion in this model. Repeated transplantation at 6 and 9 h after reperfusion suppressed inflammation and oxidative stress in ischemic brains, resulting in improved neuroprotection.


Assuntos
Transplante de Medula Óssea/métodos , Lesões Encefálicas/terapia , Ataque Isquêmico Transitório/complicações , Leucócitos Mononucleares/transplante , 8-Hidroxi-2'-Desoxiguanosina , Aldeídos/metabolismo , Animais , Lesões Encefálicas/etiologia , Proteínas de Ligação ao Cálcio/metabolismo , Desoxiguanosina/análogos & derivados , Desoxiguanosina/metabolismo , Modelos Animais de Doenças , Imuno-Histoquímica , Inflamação/etiologia , Inflamação/terapia , Masculino , Proteínas dos Microfilamentos/metabolismo , Estresse Oxidativo , Ratos , Ratos Sprague-Dawley , Fatores de Tempo , Transplante Homólogo
4.
Intern Med ; 52(1): 115-7, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23291685

RESUMO

We herein report the case of a 75-year-old woman with a paradoxical cerebral air embolism (CAE). She developed a bilateral visual disturbance at the time of needle puncture during a computed tomography (CT)-guided percutaneous needle lung biopsy in the face down position. The air density within the descending aorta on chest CT suggested the presence of a cerebral air embolism. Brain MRI demonstrated increased signal intensity in the bilateral occipital lobes on diffusion-weighted images. Usually, CAE occurs predominantly in the right hemisphere for anatomical reasons. The face down position and the anatomical features of the right subclavian artery, which diverges backward from the brachiocephalic artery, might explain such a unique distribution of CAE in this patient.


Assuntos
Biópsia por Agulha/efeitos adversos , Embolia Aérea/etiologia , Oxigenoterapia Hiperbárica/métodos , Doença Iatrogênica , Biópsia Guiada por Imagem/efeitos adversos , Neoplasias Pulmonares/patologia , Idoso , Biópsia por Agulha/métodos , Embolia Aérea/diagnóstico , Embolia Aérea/terapia , Feminino , Seguimentos , Humanos , Biópsia Guiada por Imagem/métodos , Imageamento por Ressonância Magnética/métodos , Decúbito Ventral , Doenças Raras , Medição de Risco , Tomografia Computadorizada por Raios X/métodos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA